gene in patients relapsing after procedure with the BCL2 antagonist venetoclax. sixty six Resistance to those agents has been connected with these mutations in around 70% of cases, although they are often subclonal and their unique job resulting in resistance ought to be demonstrated.Over the past decades, the amount of sufferers referred for allog